Monocyte cytokine and costimulatory molecule expression in patients infected with Leishmania mexicana

Parasite Immunology

Volumn 29, Issue 3, 2007, Pages 117-126

  Carrada, G ^a,b,c   Caneda C ^a   Salaiza, N ^a   Delgado, J ^a   Ruiz, A ^a   Sanchez, B ^c,d   Gutierrez Kobeh L ^a   Aguirre, M ^a   Becker, I ^a,b  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b Secretaria de Salud del Estado de Tabasco   (Mexico)

^c UNIVERSIDAD JUÁREZ AUTÓNOMA DE TABASCO   (Mexico)

^d PEMEX   (Mexico)

Author keywords

Costimulatory molecules; Innate cytokines; L. mexicana; Patients

Indexed keywords

B7 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 18; LIPOPHOSPHOGLYCAN; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; ANTIGEN EXPRESSION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIFFUSE SKIN LEISHMANIASIS; DISEASE SEVERITY; FEMALE; HUMAN; IN VITRO STUDY; LEISHMANIA MEXICANA; LEISHMANIASIS; LOCALIZED SKIN LEISHMANIASIS; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; ANIMALS; ANTIGENS, CD40; ANTIGENS, CD80; ANTIGENS, CD86; CYTOKINES; FEMALE; GLYCOSPHINGOLIPIDS; HUMANS; INTERLEUKIN-12; INTERLEUKIN-15; INTERLEUKIN-18; LEISHMANIA MEXICANA; LEISHMANIASIS, CUTANEOUS; LEISHMANIASIS, DIFFUSE CUTANEOUS; MALE; MEXICO; MIDDLE AGED; MONOCYTES; STATISTICS, NONPARAMETRIC; TUMOR NECROSIS FACTOR-ALPHA;

LEISHMANIA MEXICANA;

EID: 33846898733     PISSN: 01419838     EISSN: 13653024     Source Type: Journal    
DOI: 10.1111/j.1365-3024.2006.00924.x     Document Type: Article

References (45)

1. Hepburn NC. Cutaneous leishmaniasis: an overview. J Postgrad Med 2003; 49: 50-54.
2. Petersen EA, Neva FA, Oster CN & Bogaert Diaz H. Specific inhibition of lymphocyte-proliferation responses by adherent suppressor cells in diffuse cutaneous leishmaniasis. N Engl J Med 1982; 306: 387-392.
3. Castes M, Agnelli A, Verde O & Rondon AJ. Characterization of the cellular immune response in American cutaneous leishmaniasis. Clin Immunol Immunopathol 1983; 27: 176-186.
4. Velasco O, Savarino SJ, Walton BC, Gam AA & Neva FA. Diffuse cutaneous leishmaniasis in Mexico. Am J Trop Med Hyg 1989; 41: 280-288.
5. Miriam B-C, Nallely C, Marco C-R, Tayde SC, Ruy PM, Ingeborg B. Polymorphism analysis of the internal transcribed spacer and small subunit of ribosomal RNA genes of Leishmania mexicana. Parasitol Res 2002; 88: 918-925.
6. Turetz ML, Machado PR, Ko AI et al. Disseminated leishmaniasis: a new and emerging form of leishmaniasis observed in northeastern Brazil. J Infect Dis 2002; 186: 1829-1834.
7. Bomfim G, Nascimento C, Costa J, Carvalho EM, Barral-Neto M & Barral A. Variation of cytokine patterns related to therapeutic response in diffuse cutaneous leishmaniasis. Exp Parasitol 1996; 84: 188-194.
8. Locksley RM, Heinzel FP, Sadick MD, Holaday BJ & Gardner KD Jr. Murine cutaneous leishmaniasis: susceptibility correlates with differential expansion of helper T-cell subsets. Ann Inst Pasteur Immunol 1987; 138: 744-749.
9. Noben-Trauth N, Paul WE & Sacks DL. IL-4- and IL-4 receptor-deficient BALB/c mice reveal differences in susceptibility to Leishmania major parasite substrains. J Immunol 1999; 162: 6132-6140.
10. Lehmann J, Enssle KH, Lehmann I, Emmendorfer A & Lohmann-Matthes ML. The capacity to produce IFN-gamma rather than the presence of interleukin-4 determines the resistance and the degree of susceptibility to Leishmania donovani infection in mice. J Interferon Cytokine Res 2000; 20: 63-77.
11. Himmelrich H, Launois P, Maillard I et al. In BALB/c mice, IL-4 production during the initial phase of infection with Leishmania major is necessary and sufficient to instruct Th2 cell development resulting in progressive disease. J Immunol 2000; 164: 4819-4825.
12. Rogers KA, DeKrey GK, Mbow ML, Gillespie RD, Brodskyn CI & Titus RG. Type 1 and type 2 responses to Leishmania major. FEMS Microbiol Lett 2002; 209: 1-7.
13. Maioli TU, Takane E, Arantes RM, Fietto JL & Afonso LC. Immune response induced by New World Leishmania species in C57BL/6 mice. Parasitol Res 2004; 94: 207-212.
14. Babay BE, Louzir H, Kebaier C, Boubaker S, Dellagi K & Cazenave PA. Inbred strains derived from feral mice reveal new pathogenic mechanisms of experimental leishmaniasis due to Leishmania major. Infect Immun 2004; 72: 4603-4611.
15. Park AY, Hondowicz B, Kopf M & Scott P. The role of IL-12 in maintaining resistance to Leishmania major. J Immunol 2002; 168: 5771-5777.
16. Ohkusu K, Yoshimoto T, Takeda K et al. Potentiality of interleukin-18 as a useful reagent for treatment and prevention of Leishmania major infection. Infect Immun 2000; 68: 2449-2456.
17. D'Agostino P, Milano S, Arcoleo F et al. Interleukin-15, as interferon-gamma, induces the killing of Leishmania infantum in phorbol-myristate-acetate-activated macrophages increasing interleukin-12. Scand J Immunol 2004; 60: 609-614.
18. Campbell KA, Ovendale PJ, Kennedy MK, Fanslow WC, Reed SG & Maliszewski CR. CD40 ligand is required for protective cell-mediated immunity to Leishmania major. Immunity 1996; 4: 283-289.
19. Kamanaka M, Yu P, Yasui T et al. Protective role of CD40 in Leishmania major infection at two distinct phases of cell-mediated immunity. Immunity 1996; 4: 275-281.
20. Murphy ML, Engwerda CR, Gorak PM & Kaye PM. B7-2 blockade enhances T cell responses to Leishmania donovani. J Immunol 1997; 159: 4460-4466.
21. Elloso MM & Scott P. Expression and contribution of B7-1 (CD80) and B7-2 (CD86) in the early immune response to Leishmania major infection. J Immunol 1999; 162: 6708-6715.
22. Brown JA, Greenwald RJ, Scott S et al. T helper differentiation in resistant and susceptible B7-deficient mice infected with Leishmania major. Eur J Immunol 2002; 32: 1764-1772.
23. McConville MJ, Bacic A, Mitchell GF & Handman E. Lipophosphoglycan of Leishmania major that vaccinates against cutaneous leishmaniasis contains an alkylglycerophosphoinositol lipid anchor. Proc Natl Acad Sci USA 1987; 84: 8941-8945.
24. Akuffo H, Maasho K, Blostedt M, Höjeberg B, Britton S & Bakhiet M. Leishmania aethiopica derived from diffuse leishmaniasis patients preferentially induce mRNA for IL-10 while those from localized leishmaniasis patients induce interferon-gamma. J Infect Dis 1997; 175: 737741.
25. Convit J, Pinardi ME & Rondon AJ. Diffuse cutaneous leishmaniasis: a disease due to an immunological defect of the host. Trans Roy Soc Trop Med Hyg 1972; 66: 60361.
26. Wilhelm P, Ritter U, Labbow S et al. Rapidly fatal leishmaniasis in resistant C57BL/6 mice lacking TNF. J Immunol 2001; 166: 4012-4019.
27. Fonseca SG, Romao PR, Figueiredo F et al. TNF-alpha mediates the induction of nitric oxide synthase in macrophages but not in neutrophils in experimental cutaneous leishmaniasis. Eur J Immunol 2003; 33: 2297-2306.
28. Caceres-Dittmar G, Tapia FJ, Sanchez MA et al. Determination of cytokine profile in American cutaneous leishmaniasis using the polymerase chain reaction. Clin Exp Immunol 1993; 91: 500-505.
29. Habibi GR, Khamesipour A, McMaster WR & Mahboudi F. Cytokine gene expression in healing and non-healing cases of cutaneous leishmaniasis in response to in vitro stimulation with recombinant gp63 using semi-quantitative RT-PCR. Scand J Immunol 2001; 54: 414-420.
30. Scharton-Kersten T, Afonso LC, Wysocka M, Trinchieri G & Scott P. IL-12 is required for natural killer cell activation and subsequent T helper 1 cell development in experimental leishmaniasis. J Immunol 1995; 154: 5320-5330.
31. Lebel-Binay S, Berger A, Zinzindohoue F et al. Interleukin-18: biological properties and clinical implications. Eur Cytokine Netw 2000; 11: 15-26.
32. Tapia E, Perez-Jimenez E, Lopez-Fuertes L, Gonzalo R, Gherardi MM & Esteban M. The combination of DNA vectors expressing IL-12 + IL-18 elicits high protective immune response against cutaneous leishmaniasis after priming with DNA-p36/LACK and the cytokines, followed by a booster with a vaccinia virus recombinant expressing p36/LACK. Microbes Infect 2003; 5: 73-84.
33. Fehniger TA, Shah MH, Turner MJ et al. Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. J Immunol 1999; 162: 4511-4520.
34. Qadoumi M, Becker I, Donhauser N, Rollinghoff M & Bogdan C. Expression of inducible nitric oxide synthase in skin lesions of patients with American cutaneous leishmaniasis. Infect Immun 2002; 70: 4638-4642.
35. Fehniger TA & Caligiuri MA. Interleukin 15: biology and relevance to human disease. Blood 2001; 97: 14-32.
36. Milano S, Di Bella G, D'Agostino P et al. IL-15 in human visceral leishmaniasis caused by Leishmania infantum. Clin Exp Immunol 2002; 127: 360-365.
37. Kato T, Hakamada R, Yamane H & Nariuchi H. Induction of IL-12 p40 messenger RNA expression and IL-12 production of macrophages via CD40-CD40 ligand interaction. J Immunol 1996; 156: 3932-3938.
38. Zhang X, Schwartz JC, Almo SC & Nathenson SG. Crystal structure of the receptor-binding domain of human B7-2: insights into organization and signaling. Proc Natl Acad Sci USA 2003; 100: 2586-2591.
39. Bhatia S, Edidin M, Almo SC & Nathenson SG. Different cell surface oligomeric states of B7-1 and B7-2: implications for signaling. Proc Natl Acad Sci USA 2005; 102: 15569-15574.
40. Hofer MF, Jirapongsananuruk O, Trumble AE & Leung DY. Upregulation of B7.2, but not B7.1, on B cells from patients with allergic asthma. J Allergy Clin Immunol 1998; 101: 96-102.
41. Sugita S & Streilein JW. Iris pigment epithelium expressing CD86 (B7-2) directly suppresses T cell activation in vitro via binding to cytotoxic T lymphocyte-associated antigen 4. J Exp Med 2003; 198: 161-171.
42. Brown JA, Titus RG, Nabavi N & Glimcher LH. Blockade of CD86 ameliorates Leishmania major infection by downregulating the Th2 response. J Infect Dis 1996; 174: 1303-1308.
43. Liu L, Kuchroo VK, Weiner HL. B7.2 (CD86) but not B7.1 (CD80) is required for the induction of low dose oral tolerance. J Immunol 1999; 163: 2284-2290.
44. Marth T, Stober W, Seder RA & Kelsall BL. Regulation of transforming growth factor-beta production by interleukin 12. Eur J Immunol 1997; 27: 1213-1220.
45. Sutmuller RP, Morgan ME, Netea MG & Grauer O. Toll-like receptors on regulatory T cells: expanding immune regulation. Trends Immunol 2006; 27: 387-393.